| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 3.9K | 10.8% |
| Total Income | 4.0K | 9.7% |
| Expenditure | 3.9K | 1.6% |
| PBT | 96.90 | 80.1% |
| Net Profit | 89.20 | 80.6% |
| OPM | 19.00% | 5.87pp |
| NPM | 2.22% | 8.09pp |
| EPS | 0.26 | 91.0% |
Biocon Ltd Accelerates Growth with 15% YoY Revenue Increase in Q1 FY26, Launches 10th Biosimilar in Canada
14 Aug 2025 · 14 Aug 2025, 07:54 pm
Summary
Biocon Ltd has reported a 15% YoY increase in revenue for Q1 FY26. The company also launched its 10th biosimilar in Canada and secured approvals for biosimilar Denosumab from the European Commission and U.K. MHRA. Biocon Biologics' injectables facility for GLP-1s has been commissioned and Syngene inaugurated a state-of-the-art Peptide laboratory. The company continues to make significant strides in its sustainability journey.
Key Highlights
- 1
15% YoY revenue increase in Q1 FY26
- 2
Launched 10th biosimilar in Canada
- 3
Secured approvals for biosimilar Denosumab from European Commission and U.K. MHRA
- 4
Commissioned injectables facility for GLP-1s
- 5
Inaugurated a state-of-the-art Peptide laboratory at Syngene
- 6
Received a Gold rating in the 2024 EcoVadis Corporate Sustainability Assessment
- 7
Syngene recognized by Time Magazine and Statista as one of the world's most sustainable companies in 2025
Management Comments
Dr. Kiran Mazumdar Shaw
We launched the first biosimilar Aflibercept, Yesafili™, in Canada. And this marks our tenth biosimilar to reach commercial markets globally, underscoring our expanding global footprint.
Informational and educational content only. Not investment advice.